AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.

AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.

The article compares Amgen, an established biotech giant with $36.7B in revenue and strong profitability, against Revolution Medicines, a clinical-stage oncology company with no approved products but a breakthrough cancer therapy (Daraxonrasib) that showed 50%+ reduction in death risk for metastatic pancreatic cancer. The author recommends Revolution Medicines for long-term investors willing to accept biotech risk, citing the paradigm-shifting potential of its RAS-targeted cancer pipeline, despite current losses and competitive pressures.

Cencora's U.S. Healthcare Solutions business demonstrated accelerating momentum with 5% revenue growth and 16% operating income growth in Q3, driven by specialty strength and OneOncology's performance. However, the company faces headwinds from manufacturer list-price reductions, the pending MWI divestiture expected to create a $150 million earnings impact, and regulatory uncertainty around 340B and ASP rules. GLP-1 growth and international operations provide diversification opportunities.

AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.

Cencora reported Q3 fiscal 2026 adjusted EPS of $4.48, beating consensus estimates by 2.5%, with 12% year-over-year earnings growth. Revenue rose 5.1% to $84.76 billion but slightly missed expectations. The company raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 and increased operating income growth outlook to 13-14%. However, post-earnings estimates have trended downward, and the stock received a Zacks Rank #3 (Hold) rating.

Cencora (COR) raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 following stronger-than-expected third-quarter results. The company's U.S. segment profit grew 15.9% driven by specialty sales and GLP-1 demand, while international operating income rose 20.8%. However, headwinds from lower-margin GLP-1 products, manufacturer price reductions, and higher financing costs tempered upside. The stock maintains a Zacks Rank #3 (Hold) rating.

Cardinal Health's generics business continues to be a steady profit contributor, with fiscal 2026 volume growth exceeding long-term planning assumptions of 2-3%. The company expects fiscal 2027 to benefit from new generic launches, brand-to-generic conversions, and stable Red Oak program dynamics, supporting projected Pharma segment profit growth of 8-11%. Peers McKesson and Cencora also show strength in their pharmaceutical distribution and generics portfolios.

Zacks highlights strong stock performance from its various rating systems and portfolios. Accelerant gained 53.7% after a Zacks Rank upgrade, while Shopify and Broadridge Financial gained 28.8% and 19.5% respectively over 12 weeks. General Mills climbed 22.9% as investors favored dividend stocks amid market volatility. The article demonstrates the effectiveness of Zacks' research methodologies across multiple portfolio strategies despite economic headwinds including sticky inflation and slowing consumer confidence.

The Schall Law Firm is investigating Cencora, Inc. for potential securities law violations following the company's Q2 2026 earnings miss and guidance reduction on May 6, 2026. Cencora attributed a $2 billion revenue headwind to manufactured list price reductions, causing its stock to plummet 17.4% on the announcement. The investigation focuses on whether the company issued false or misleading statements or failed to disclose material information to investors.